Navigation Links
Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that survival and sub-population data from the Phase 2b clinical trial in metastatic melanoma of the Company's lead oncology drug candidate, STA-4783, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on Tuesday, June 5, 2007. In this double-blind, randomized, multi-center trial, patients treated with STA-4783 in combination with paclitaxel were compared with patients treated with paclitaxel alone. All patients had stage IV metastatic melanoma.

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, controlled, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

The schedule and meeting places for the presentation, together with the abstract numbers, are listed below:

Poster Presentations

Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Presentation: 17

Abstract No. 8528

"Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-47
'"/>




Page: 1 2 3

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Pharmaceuticals to Host Conference Call Today
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
9. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
10. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
11. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
(Date:5/22/2013)... LEWIS CENTER, Ohio , May 22, 2013 ... of Opioid Defense Manager™ (ODM).  Launched in November ... Medical,s revolutionary managed care program to stop the ... ODM is a proactive, customized program designed to ... drug use while maintaining the necessary balance to ...
(Date:5/22/2013)... -- Z-Medica, a leading developer and marketer of hemostatic ... of products designed to meet the unique needs of ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ® ... custom-designed to help responders stop bleeding fast and keep ... hospital or trauma center. The line includes products designed ...
(Date:5/22/2013)... MAPLE GROVE, Minn. , May 22, ... today announced the successful completion of its ... (extended-release topiramate), an internally developed program for ... the company,s proprietary formulation technology.  USL255 is ... and reduce fluctuations in topiramate blood levels ...
Breaking Medicine Technology:Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4
... SAN DIEGO, Feb. 18, 2011 Zimmer Holdings, Inc. (NYSE: ... care, today announced it has received FDA clearance for the ... TM-S system is the industry,s first cervical interbody device incorporating ... device for cervical interbody fusion (IBF) in the United ...
... Bellicum Pharmaceuticals, Inc. today announced the presentation ... BPX-101, a novel drug-activated dendritic cell vaccine for ... separate posters at the 2011 Genitourinary Cancers Symposium ... 19, 2011. Three leading medical specialty societies co-sponsor ...
Cached Medicine Technology:Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 2Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device 3Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine 2Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine 3
(Date:5/22/2013)... Brook, New York (PRWEB) May 22, 2013 ... that specializes in combining treatments for optimal results, is ... thin skin on the neck. The practice has ... seen dramatic results. , “Basically, this approach is for ... lift,” says Westchester dermatologist Dr. Michelle Abadir ...
(Date:5/22/2013)... of the antidepressant Lexapro appears to help prevent ... study finds. The condition is known ... people with this condition may not develop noticeable ... blood supply, according to researchers from Duke University ... the researchers found that people taking the antidepressant ...
(Date:5/22/2013)... research from Brigham and Women,s Hospital (BWH) finds that ... but deadly lung disease, may be effective in identifying ... will be presented at the American Thoracic Society International ... England Journal of Medicine on May 22 and ... "While this variant of the MUC5B gene is fairly ...
(Date:5/22/2013)... May 22, 2013 The PreDiabetes Center ... participation in the Greater Philadelphia Tour de Cure, a premier ... who are passionate about stopping the spread of diabetes ... Americans. , The Tour de Cure will take place ... Meetinghouse Road in Ambler, 30 minutes outside of Philadelphia, between ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Following the ... fitness franchise Fit Body Boot Camp Kincardine ... 1,000 lb. Meltdown Challenge starting on June 3rd at ... Centre 601 Durham Street, Kincardine, Ontario.     , Fit Body ... inspire and motivate local community residents to lose a ...
Breaking Medicine News(10 mins):Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... Favorite, and ,Have Fun Helping It ... ... Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude of Richard ... debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: SuperLife founder ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bullion ... medicinal and diagnostic products in China,today announced that ... Company,s Form 10QSB for the fiscal quarters ended ... filed its full year 2006 amendments on,November 8, ...
... 18 Escalon Medical Corp.,(Nasdaq Capital Market: ESMC) ... clearance from the U.S. Food and Drug,Administration (FDA) ... differential Hematology Analyzer. Drew Scientific plans to,commence shipments ... month-end., "The FDA clearance represents a major ...
... PHILADELPHIA A new brain imaging study by researchers ... Pennsylvania shows that cigarette cravings in smokers who are ... specific regions of the brain. Using a novel method ... MD, associate professor of Neurology at Penn, this study ...
... (NYSE: CDI ),announced today that the Life ... been awarded a contract from CJ CheilJedang,Corporation to ... manufacturing complex to be located in Osong, Korea. ... center for global,distribution of oral solid and sterile ...
... where he worked as a ... ... Dikembe,Mutombo, who is known as much for his philanthropy as his storied ... organization prepare its entry into his home country, the,Democratic Republic of Congo ...
Cached Medicine News:Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:New neuroimaging study identifies 'brain signature' for cigarette cravings 2Health News:CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 3Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 4
... the hand, the Jarvik 2000 pump is about ... welded titanium shell sits a direct-current motor, a ... single moving part: a small, spinning titanium impeller ... to 7 liters per minute. Rather than take ...
... cardiac assist system primarily designed as a permanent ... failure., ,It is a blood pump that connects ... to help the ailing hearts pumping function and ... , ,It can also be used as a ...
... The Masimo SET LNOP Blue Sensor is ... babies. The LNOP Blue sensor is ... accuracy claims for cyanotic infants and children. ... presented challenging conditions for reliable and accurate ...
... The Trinity Biotech Captia™ Varicella-Zoster Virus (VZV) ... for the detection and quantitative determination of ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
Medicine Products: